Medical Oncology & Breast Unit, "A. Perrino" Hospital, Brindisi, Italy.
Medical Oncology & Breast Unit, "A. Perrino" Hospital, Brindisi, Italy.
Crit Rev Oncol Hematol. 2015 Jun;94(3):291-301. doi: 10.1016/j.critrevonc.2015.01.001. Epub 2015 Jan 10.
Endocrine therapy is the recommended systemic therapy for hormone receptor (HR) positive metastatic breast cancer (MBC). However so far the limited number of endocrine agents and the onset of endocrine resistance have severely limited the therapeutic options for this patients. In the last years many targeted agents have been investigated to prevent or overcome endocrine resistance; only a few of them have been found effective in HR positive MBC, such as everolimus, CK4/6 inhibitors and HDAC inhibitors. Furthermore, translational medicine studies using next generation sequencing technologies have evaluated genetic variations of a broad panel of cancer-related genes and explored their correlations with targeted agents benefit. In some studies predictive biomarkers have been identified and many ongoing studies are evaluating the efficacy of targeted drugs in HR positive MBC patients selected for biomarkers or stratified by pathways amplification.
内分泌治疗是激素受体（HR）阳性转移性乳腺癌（MBC）的推荐全身治疗方法。然而，到目前为止，有限数量的内分泌药物和内分泌抵抗的发生严重限制了此类患者的治疗选择。在过去的几年中，已经研究了许多靶向药物来预防或克服内分泌抵抗；只有少数几种药物在 HR 阳性 MBC 中被发现有效，如依维莫司、CK4/6 抑制剂和 HDAC 抑制剂。此外，使用下一代测序技术的转化医学研究评估了广泛的癌症相关基因的遗传变异，并探讨了它们与靶向药物疗效的相关性。在一些研究中，已经确定了预测性生物标志物，许多正在进行的研究正在评估针对生物标志物选择或按途径扩增分层的 HR 阳性 MBC 患者中靶向药物的疗效。
